Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Finished Goods (2025)

Historic Finished Goods for Outlook Therapeutics (OTLK) over the last 1 years, with Q3 2025 value amounting to $29626.0.

  • Outlook Therapeutics' Finished Goods changed N/A to $29626.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29626.0, marking a year-over-year change of. This contributed to the annual value of $29626.0 for FY2025, which is N/A changed from last year.
  • Per Outlook Therapeutics' latest filing, its Finished Goods stood at $29626.0 for Q3 2025.
  • Outlook Therapeutics' 5-year Finished Goods high stood at $3.3 million for Q1 2025, and its period low was $29626.0 during Q3 2025.